SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cost-Effectiveness and Economic Impact of Bladder Cancer Management: An Updated Review of the Literature
8 references·0 citing·30 second hop
Cost-Effectiveness and Economic Impact of Bladder Cancer Management: An Updated Review of the Literature (2023)Cost-Effectiveness and Economic Impact of…Medical Care Costs Associated with Cancer Survivorship in the United States (2020)Medical Care Costs Associated…Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer (2018)Cost-effectiveness of Pembrol…Trajectories of Injectable Cancer Drug Costs After Launch in the United States (2017)Trajectories of Injectable Ca…Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries (2017)Rising Prices of Targeted Ora…Economic Burden of Bladder Cancer Across the European Union (2015)Economic Burden of Bladder Ca…The burden of bladder cancer care (2014)The burden of bladder cancer …National Trends In Spending On And Use Of Oral Oncologics, First Quarter 2006 Through Third Quarter 2011 (2014)National Trends In Spending O…The health economics of bladder cancer (2003)The health economics of bladd…Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs (2009)Projections of the Cost of Cancer Care in the United States: 2010-2020 (2011)Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia (2013)Economic burden of cardiovascular diseases in the enlarged European Union (2006)Economic burden of cancer across the European Union: a population-based cost analysis (2013)ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe (2016)The cost of cancer in Europe 2018 (2020)Economic Perspective of Cancer Care and Its Consequences for Vulnerable Groups (2022)Medicare Payments from Diagnosis to Death for Elderly Cancer Patients by Stage at Diagnosis (1995)Washington State Cancer Patients Found To Be At Greater Risk For Bankruptcy Than People Without A Cancer Diagnosis (2013)Financial Hardships Experienced by Cancer Survivors: A Systematic Review (2016)Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer (2016)Medical Financial Hardship among Cancer Survivors in the United States: What Do We Know? What Do We Need to Know? (2018)Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies (2019)Financial Toxicity in Advanced and Metastatic Cancer: Overburdened and Underprepared (2019)The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts (2013)Bringing down the cost of cancer treatment (2018)Delivery of Financial Navigation Services within National Cancer Institute-Designated Cancer Centers (2021)How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. (1992)Net Health Benefits (1998)Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold (2014)Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib—A cost-effectiveness analysis (2018)Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China (2019)Cost of Care for Elderly Cancer Patients in the United States (2008)American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options (2015)Financial toxicity in cancer care: origins, impact, and solutions (2021)Navigating financial toxicity in patients with cancer: A multidisciplinary management approach (2022)The Economic Burden of Racial, Ethnic, and Educational Health Inequities in the US (2023)Clinical model of lifetime cost of treating bladder cancer and associated complications (2006)Financial Toxicity among Patients with Bladder Cancer: Reasons for Delay in Care and Effect on Quality of Life (2017)
this work references cited by second hop

References

  • 2003The health economics of bladder cancer865 cited
  • 2020Medical Care Costs Associated with Cancer Survivorship in the United States643 cited
  • 2015Economic Burden of Bladder Cancer Across the European Union332 cited
  • 2014The burden of bladder cancer care197 cited
  • 2017Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries114 cited
  • 2017Trajectories of Injectable Cancer Drug Costs After Launch in the United States108 cited
  • 2018Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer63 cited
  • 2014National Trends In Spending On And Use Of Oral Oncologics, First Quarter 2006 Through Third Quarter 201155 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work